A detailed history of Lazard Asset Management LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 65 shares of IOVA stock, worth $555. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65
Previous 226 71.24%
Holding current value
$555
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.28 - $11.9 $1,172 - $1,915
-161 Reduced 71.24%
65 $0
Q2 2024

Aug 14, 2024

SELL
$7.78 - $14.19 $28,334 - $51,679
-3,642 Reduced 94.16%
226 $1,000
Q1 2024

May 14, 2024

SELL
$7.59 - $17.47 $16,189 - $37,263
-2,133 Reduced 35.54%
3,868 $56,000
Q4 2023

Feb 14, 2024

BUY
$3.3 - $8.89 $7,656 - $20,624
2,320 Added 63.03%
6,001 $48,000
Q3 2023

Nov 14, 2023

BUY
$4.44 - $8.79 $648 - $1,283
146 Added 4.13%
3,681 $16,000
Q2 2023

Aug 14, 2023

BUY
$5.36 - $9.06 $611 - $1,032
114 Added 3.33%
3,535 $24,000
Q1 2023

May 15, 2023

BUY
$5.53 - $8.22 $3,865 - $5,745
699 Added 25.68%
3,421 $20,000
Q4 2022

Feb 14, 2023

SELL
$5.62 - $10.0 $4,327 - $7,700
-770 Reduced 22.05%
2,722 $17,000
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $171 - $235
18 Added 0.52%
3,492 $32,000
Q2 2022

Aug 09, 2022

BUY
$6.38 - $18.33 $746 - $2,144
117 Added 3.49%
3,474 $37,000
Q1 2022

May 13, 2022

BUY
$12.38 - $19.1 $11,562 - $17,839
934 Added 38.55%
3,357 $55,000
Q4 2021

Feb 09, 2022

BUY
$16.55 - $27.63 $7,033 - $11,742
425 Added 21.27%
2,423 $46,000
Q3 2021

Nov 15, 2021

SELL
$20.35 - $26.63 $20,512 - $26,843
-1,008 Reduced 33.53%
1,998 $48,000
Q2 2021

Aug 12, 2021

BUY
$16.33 - $33.07 $48,091 - $97,391
2,945 Added 4827.87%
3,006 $77,000
Q4 2020

Feb 11, 2021

BUY
$28.04 - $50.26 $1,710 - $3,065
61 New
61 $2,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.35B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.